News | April 28, 2026
Aurigene bets big on CRDMO expansion with $100 million outlay
Deploys $40 million in Hyderabad; advances APIs, peptides, and global small molecule capabilities
Deploys $40 million in Hyderabad; advances APIs, peptides, and global small molecule capabilities
The first of four planned modules at the new plant is expected to come online by summer 2026
These building blocks are essential to modern therapeutics, including fast-growing GLP-1 treatments for weight loss and diabetes
Accelerating hit-to-lead timelines, and strengthening end-to-end drug discovery and development services
The Swiss peptide and oligonucleotide manufacturers roll out major investments across site networks in US, UK and Switzerland
PAT stood at Rs. 88 crore for Q4 FY25 as compared to Rs. 56 crore in Q4FY24, an increase of 57%
Strengthening capabilities in Peptide Therapeutics and CDMO services
The Peptide Research Center is designed to support innovator pharma and biotech companies with specialized services across peptide synthesis, discovery, and advanced modalities, including complex conjugates
The acquisition aligns with Granules' vision to enter the rapidly expanding peptide-based anti-diabetic and anti-obesity market
Site Enhances New Modality CRDMO Platform Capacity for Customers
Subscribe To Our Newsletter & Stay Updated
